Literature DB >> 26151887

Reference intervals of plasma matrix metalloproteinases 2, 3, and 9 and serum asymmetric dimethylarginine levels.

Pavlina Kusnierova1, Frantisek Vsiansky, Leos Pleva, Pavlina Plevova, Kristian Safarcik, Zdenek Svagera.   

Abstract

OBJECTIVE: The present study aimed to verify the reference intervals of plasma matrix metalloproteinases (MMPs) 2, 3, and 9 and serum asymmetric dimethylarginine (ADMA) in a healthy population with an average age corresponding to that of patients with cardiovascular diseases.
METHODS: The study included 180 healthy volunteers. Plasma MMP-2, MMP-3, MMP-9, and serum ADMA levels were determined using an enzyme-linked immunosorbent assay. These levels were analyzed for association with age and gender. The Cbstat5, R software, and NCSS 2007 programs were used for statistical analysis.
RESULTS: The average volunteer age was 47.4 years in the group in which MMP-3 and ADMA were analyzed, 40.3 years in the MMP-9 group, and 47.8 years for the MMP-2 group. Serum ADMA levels were determined to be independent of age and gender. Plasma MMP-2 levels were significantly correlated with age (p = 0.001), with lower levels detected in persons ≤ 49 years of age. Plasma MMP-3 was significantly associated with both age (p < 0.0001) and gender, with lower levels detected in persons of ≤ 47 years of age and among women. Plasma MMP-9 levels were not age dependent, but were associated with gender (p = 0.014), showing lower levels in women.
CONCLUSIONS: Reference intervals of heparin-plasma MMP-2, MMP-3, and MMP-9 and serum ADMA levels were determined. MMP-2 and MMP-3 levels were found to be age dependent, and MMP-3 and MMP-9 levels were gender dependent.

Entities:  

Keywords:  Adult; age dependence; atherosclerosis; cardiovascular diseases; enzyme-linked immunosorbent assay; gender dependence

Mesh:

Substances:

Year:  2015        PMID: 26151887     DOI: 10.3109/00365513.2015.1057760

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  5 in total

1.  Association between asymmetric dimethylarginine serum levels and left ventricular longitudinal deformation in patients with normal ejection fractions: a two-dimensional speckle-tracking echocardiography examination.

Authors:  Ali Hosseinsabet; Niloofar Akavan-Khaleghi; Reza Mohseni-Badalabadi
Journal:  Cardiovasc Endocrinol Metab       Date:  2018-11-14

Review 2.  Asymmetric Dimethylarginine and Its Relation As a Biomarker in Nephrologic Diseases.

Authors:  Mustafa E Sitar
Journal:  Biomark Insights       Date:  2016-12-07

3.  Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study.

Authors:  Atul Goyale; Anjly Jain; Colette Smith; Margarita Papatheodoridi; Marta Guerrero Misas; Davide Roccarina; Laura Iogna Prat; Dimitri P Mikhailidis; Devaki Nair; Emmanuel Tsochatzis
Journal:  PLoS One       Date:  2021-11-23       Impact factor: 3.240

4.  Serum matrix metalloproteinase-2 as a predictor of level of hypoxemia and severity of obstructive sleep apnea.

Authors:  Aleksandra Franczak; Robert Skomro; Jolanta Sawicka; Iwona Bil-Lula; Andrhea Nocon; Mark Fenton; Joshua Lawson; Grzegorz Sawicki
Journal:  Sleep Breath       Date:  2020-10-01       Impact factor: 2.816

5.  Levels of matrix metalloproteinases differ in plasma and serum - aspects regarding analysis of biological markers in cancer.

Authors:  Andreas Jonsson; Claes Hjalmarsson; Peter Falk; Marie-Lois Ivarsson
Journal:  Br J Cancer       Date:  2016-05-17       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.